Abstract：Objective: To explore the effects and safety of Huangqi capsule combined with cefoperazone-sulbactam and tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii (MDRAB) pneumonia. Methods: The clinical data of 52 cases of MDRAB pneumonia treated with cefoperazone sulbactam + tegacyclin (control group) and Huangqin capsule + cefoperazone sulbactam + tegacyclin (observation group) were analyzed retrospectively. The bacterial clearance, state of recovery (time of normal temperature recovery, Rale disappearance, lung shadow disappearance) and adverse reactions were recorded, and the infection status (PCT, MMP-9), TCM syndrome (tcmsss), lung injury (lung injury) were compared before and after treatment for 2 weeks Score (LIS)] difference. Results: The bacterial clearance in observation group was significantly better than that in control group (P<0.05), and the normal recovery time of body temperature, disappearance time of rales, disappearance time of lung shadow and total incidence rate of adverse reactions during treatment were significantly lower than those in control group (P<0.05). After 2周 of treatment, the scores of infection status (serum PCT, MMP-9), TCM syndrome (TCMSSS score) and lung injury (LIS score) were lower than those before treatment (P<0.05), and the scores in observation group were lower than those in control group (P<0.05). Conclusion: Huangqi capsule assisted with cefoperazone-sulbactam and tigecycline has significant effects in the treatment of MDRAB pneumonia, and it can also reduce the risk of adverse reactions and has high clinical application value.
杨帅, 张明月, 康孟杰, 富雅竹. 黄芩胶囊辅助头孢哌酮舒巴坦替加环素治疗MDRAB肺炎的效果及安全性分析[J]. 河北医学, 2020, 26(2): 275-277.
YANG Shuai, ZHANG Mingyue, KANG Mengjie, et al. Analysis on the Effects and Safety of Huangqi Capsule Assisted with Cefoperazone-sulbactam and Tigecycline in the treatment of MDRAB Pneumonia. HeBei Med, 2020, 26(2): 275-277.
2020, Vol. 26 
冀公网安备13080202000677号